Neutrophil-lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry
- PMID: 40392481
- PMCID: PMC12331782
- DOI: 10.1007/s11739-025-03955-x
Neutrophil-lymphocyte ratio is associated with worse outcomes in patients with cirrhosis: insights from the PRO-LIVER Registry
Abstract
Background: Liver cirrhosis (LC) is a leading global cause of morbidity and mortality, with inflammation playing a key role in disease progression and clinical complications of LC. The Neutrophil/Lymphocyte Ratio (NLR), a readily available marker of systemic inflammation, has been linked to short-term adverse outcomes in LC, but data on long-term follow-up are limited. This study aimed to investigate the relationship between NLR and long-term all-cause mortality in an unselected cohort of LC patients.
Methods: Data were gathered from the Italian multicenter observational study "PRO-LIVER". Patients with available data to calculate NLR at baseline were included. Baseline clinical determinants of NLR and the association of NRL with all-cause mortality at 2-year follow-up were evaluated.
Results: From the overall cohort (n = 753), 506 patients with LC (31% female, mean age 64.8 ± 11.9 years) were included in the analysis. Median value of NLR was 2.42 (Interquartile Range [IQR]: 1.61-3.52). At baseline, patients with NLR ≥ 2.42 were more likely to have Child-Pugh B or C, hepatocellular carcinoma (HCC), or portal vein thrombosis (PVT). After a median follow-up of 21 months, 129 patients died: 44 (17%) with NLR < 2.42 and 85 (34%) with NLR ≥ 2.42 (p < 0.001). At multiple-adjusted Cox regression analysis, NLR ≥ 2.42 was independently associated with all-cause mortality (HR: 1.65; 95% CI: 1.12-2.44; p = 0.012), along with age, Child-Pugh C class, HCC and PVT.
Conclusions: NLR is associated with long-term all-cause mortality in LC. NLR may serve as a potentially easily available tool to aid risk refinement in LC.
Trial registration number: ClinicalTrials.gov Identifier: NCT01470547.
Keywords: Cirrhosis; Inflammation; Mortality; Neutrophil–lymphocyte ratio.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Human and animal rights: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from all individual participants included in the study.
Figures
Similar articles
-
Prognostic value of neutrophil-to-lymphocyte ratio in septic patients with liver cirrhosis: a cohort study.BMC Gastroenterol. 2025 Aug 1;25(1):549. doi: 10.1186/s12876-025-04157-7. BMC Gastroenterol. 2025. PMID: 40751177 Free PMC article.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Correlation of Neutrophil-to-Lymphocyte Ratio with Severity of Chronic Liver Disease Based on Child-Turcotte-Pugh and MELD-Na Score.J Assoc Physicians India. 2025 Jul;73(7):21-24. doi: 10.59556/japi.73.1038. J Assoc Physicians India. 2025. PMID: 40836716
-
Tamoxifen for adults with hepatocellular carcinoma.Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2. Cochrane Database Syst Rev. 2024. PMID: 39132750 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- García-Escobar A, Vera-Vera S, Tébar-Márquez D et al (2023) Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: new insights for a potential predictor of anti-cytokine therapy responsiveness. Microvasc Res 150:104598. 10.1016/j.mvr.2023.104598 - PubMed